Skip to main content
IMS Events Main banner
    22nd International Myeloma Society Annual Meeting

    Poster Discussion

    Thursday, September 18, 2025
    12:00 - 12:50 East Coast USA Time
    Location: Room 714A

    Presentations:

    • 12:00 - 12:02 East Coast USA Time
      Introduction
    • 12:02 - 12:08 East Coast USA Time
      (PA-084) Drivers of Primary Resistance to BCMA-targeted T Cell Redirected Therapies in High Tumor Burden

      Abstract Presenter: Kirsten Pfeffer, PhD – Mayo Clinic

    • 12:08 - 12:14 East Coast USA Time
      (PA-488) Efficacy and Safety of a China-Developed BCMATargeted CAR-T Therapy (Eque-cel) in Plasma Cell Leukemia: Real-World Multicenter Experience

      Abstract Presenter: Jin Lu, Professor – Peking University People's Hospital

    • 12:14 - 12:20 East Coast USA Time
      (PA-520) Efficacy and Safety of Low-frequency Daratumumab in Systemic Light-chain Amyloidosis

      Abstract Presenter: Zhen Cai, MD (she/her/hers) – Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University

    • 12:20 - 12:26 East Coast USA Time
      (PA-379) Health-Related Quality of life (HRQoL) in Frail Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Isatuximab (Isa), Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) vs VRd Alone

      Abstract Presenter: Robert Z. Orlowski, MD, PhD (he/him/his) – Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center

    • 12:26 - 12:32 East Coast USA Time
      (PA-064) Linvoseltamab (LINVO) + Carfilzomib (CFZ) in Patients ( pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Initial Results from the LINKERMM2 Trial

      Abstract Presenter: Salomon Manier, MD, PhD – Hematology Department, Lille University Hospital, Lille, France

    • 12:32 - 12:38 East Coast USA Time
      PA-355: Real-World Impact of Anti-CD38 Monoclonal Antibodies and Hematopoietic Stem Cell Transplant in Primary Plasma Cell Leukemia (2021 IMWG Criteria): A Single-Center Analysis

      Abstract Presenter: Vincent Luong, MD (he/him/his) – Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institutet and Department of Hematology, Karolinska University Hospital, Sweden

    • 12:38 - 12:44 East Coast USA Time
      (PA-145) Treatment-Free Hospitalization-Free Time With CAR T-Cell Therapy Versus Standard Regimens and Quality of Life Implications in Patients With Relapsed/Refractory MM: Findings From the KarMMa-3 Trial

      Abstract Presenter: Krina K. Patel, MD, MSc (she/her/hers) – Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center

    • 12:44 - 12:50 East Coast USA Time
      (PA-295) Tumor-reactive γδ T Cells Mediate Responses to the Antibody Drug Conjugate Belantamab Mafodotin in Multiple Myeloma

      Abstract Presenter: Liam D. Hendrikse, PhD – University Health Network